News Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:45:02 06/03/2026 am IST			5-day change	1st Jan Change
238.38 ^USD	-2.82%		-2.51%	+14.70%

01:33am	US FDA approves Johnson & Johnson's blood cancer drug after speedy review	RE
01:29am	Johnson & Johnson's Janssen Biotech Unit Secures US FDA Approval for Multiple Myeloma Treatment	MT

All News

01:33am	US FDA approves Johnson & Johnson's blood cancer drug after speedy review	RE
01:29am	Johnson & Johnson's Janssen Biotech Unit Secures US FDA Approval for Multiple Myeloma Treatment	MT
12:50am	US FDA approves JNJ's blood cancer drug	RE
12:14am	Fda grants third approval under National Priority Voucher program	RE
10:05pm	United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says	MT
08:01pm	Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion	PR
08:01pm	Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion	AQ
06:50pm	The Year the Easy Narrative Broke
04:06pm	JPMorgan Adjusts Price Target on Johnson & Johnson to $250 From $225, Maintains Neutral Rating	MT
12:49pm	Markets rebound as risks linger
10:58am	Coloplast Appoints Gavin Wood as New CEO	FW
10:27am	Coloplast Names New CEO	MT
05/03	Johnson & Johnson launches website for direct-to-consumer sales	RE
05/03	J&J has launched J&J Direct website to sell drugs direct to U.S. consumers	RE
04/03	Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus	AQ
04/03	China commerce vice minister met with Johnson & Johnson VP	RE
03/03	Johnson & Johnson Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:10 AM
03/03	Johnson & Johnson Therapy Nipocalimab Granted U.S. FDA Fast Track designation in systemic lupus erythematosus	CI
03/03	Johnson & Johnson therapy nipocalimab granted U.S. FDA fast track designation in systemic lupus erythematosus (SLE)	RE
03/03	Johnson & Johnson Says US FDA Grants Fast Track Designation to Lupus Drug Nipocalimab	MT
03/03	Johnson & Johnson Gets FDA Fast-Track Designation for Nipocalimab in Systemic Lupus Erythematosus	DJ
03/03	/C O R R E C T I O N -- Johnson & Johnson/	PR
03/03	Johnson & Johnson to Host Investor Conference Call on First-Quarter Results	BU
02/03	United Therapeutics' drug slows progression of rare lung condition in late-stage study	RE
27/02	Johnson & Johnson Announces Preliminary Results From Phase 1b Study Of Pasritamig In Combination With Docetaxel In Advanced Prostate Cancer	CI